BMO Capital analyst Do Kim maintained a Hold rating on Constellation Pharmaceuticals (NASDAQ:CNST) on Monday, setting a price target of $34, which is approximately 0.47% above the present share price of $33.84.
Kim expects Constellation Pharmaceuticals to post earnings per share (EPS) of -$0.84 for the second quarter of 2021.
The current consensus among 10 TipRanks analysts is for a Hold rating of shares in Constellation Pharmaceuticals, with an average price target of $39.88.
The analysts price targets range from a high of $75 to a low of $24.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $0 and a net profit of -$40.23 million. The company's market cap is $1.62 billion.
According to TipRanks.com, BMO Capital analyst Do Kim is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 18.1% and a 52.36% success rate.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The company utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product candidates include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA.